Business
Tech Giants' Earnings Show Diverging Paths
Eli Lilly and Novo Nordisk's latest earnings reports highlight the widening gap between them, with Lilly leading in obesity treatments while Novo struggles to regain market share. Meanwhile, Datadog’s stock faces pressure despite beating expectations.
Coverage timeline — 3 articles
CNBC
Demis Hassabis’ new role highlights the tension between his scientific ambitions and Google’s pressure to commercialize and scale AI.
2026-08-06 13:15 UTC
CNBC
As Lilly widens its lead in the obesity race, Novo is still racing to win back market share and restore investor confidence in its pipeline.
2026-08-06 13:45 UTC
MarketWatch
The cloud-monitoring company faced a high bar due to its strong stock performance this year and ended up beating expectations by less than it did in the prior quarter.
2026-08-06 13:46 UTC